INMB Q2 2019 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$428,000

Net Income

-$392,000

EPS (Diluted)

$-0.04

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$974,696

Balance Sheet

Total Assets

$28M

Total Liabilities

$692,689

Stockholders' Equity

$27M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$428,000	-$6M	+93.1%
Net Income	-$392,000	-$6M	+93.7%